Capitalizator.

Capitalize Yourself: Right Data. Real Growth.

Company Analysis

ESPR Insider Trading

Esperion Therapeutics, Inc. | Pharmaceutical Preparations

Comprehensive Trading Performance Summary

The investment history of corporate insiders at Esperion Therapeutics, Inc. provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Pharmaceutical Preparations sector.

Transactions on Chart

Open Full Chart
Filing Date Trade Date Reporting Person Relationship Type Price Qty Total, $ Owned After Change, %
2018-08-06 22:23 2018-08-03 BIOTECH TARGET N V 10% owner BUY $46.14 50,000 $2,306,970 3,282,964 +1.5%
2018-07-13 18:45 2018-07-12 BIOTECH TARGET N V 10% owner BUY $41.77 50,000 $2,088,300 3,232,964 +1.6%
2018-07-03 18:55 2018-06-29 BIOTECH TARGET N V 10% owner BUY $39.48 50,000 $1,973,805 3,182,964 +1.6%
2018-06-25 19:43 2018-06-21 BIOTECH TARGET N V 10% owner BUY $38.57 60,000 $2,314,224 3,132,964 +2.0%
2018-06-11 21:59 2018-06-07 BIOTECH TARGET N V 10% owner BUY $37.79 60,000 $2,267,292 3,072,964 +2.0%
2018-06-07 21:34 2018-06-05 BIOTECH TARGET N V 10% owner BUY $38.47 60,000 $2,308,440 3,012,964 +2.0%
2018-05-22 22:49 2018-05-18 BIOTECH TARGET N V 10% owner BUY $40.11 130,000 $5,213,767 2,952,964 +4.6%
2018-03-30 02:47 2018-03-29 NEWTON ROGER S Director SELL $72.37 25,000 $1,809,278 623,726 -3.9%
2018-01-27 01:24 2018-01-25 VITULLO NICOLE Director OPT+S $71.79 11,674 $838,076 15,329 0.0%
2017-12-09 00:14 2017-12-06 VITULLO NICOLE Director SELL $53.85 9,326 $502,205 25,927 -26.5%
2017-03-23 23:45 2017-03-21 JANNEY DANIEL Director SELL $45.80 350,000 $16,029,265 1,359,967 -20.5%
2017-03-23 23:37 2017-03-21 GOLDSTEIN DOV A MD Director SELL $41.66 800,000 $33,327,120 837,125 -48.9%
2017-03-22 15:02 2017-03-21 OMENN GILBERT S Director BUY $42.26 1,000 $42,260 1,000 +100.0%
2016-11-04 00:58 2016-11-01 Lalwani Narendra D. Officer - Chief Operating Officer BUY $9.93 5,000 $49,650 5,000 +100.0%
2016-07-07 14:17 2016-07-05 MCGOVERN MARK E Director BUY $10.00 5,000 $50,000 5,000 +100.0%
2016-05-05 14:33 2016-05-04 MAYLEBEN TIMOTHY M Director, Officer - President & CEO BUY $14.85 7,000 $103,950 41,614 +20.2%
2016-03-02 15:23 2016-03-01 OMENN GILBERT S Director BUY $15.28 5,000 $76,400 10,000 +100.0%
2016-01-29 02:22 2016-01-27 MAYLEBEN TIMOTHY M Director, Officer - President & CEO BUY $15.88 3,600 $57,168 34,614 +11.6%
2016-01-19 15:16 2016-01-15 MAYLEBEN TIMOTHY M Director, Officer - President & CEO BUY $14.08 7,200 $101,376 31,014 +30.2%
2015-04-28 01:33 2015-04-23 Aisling Capital II LP 10% owner SELL $108.22 217,469 $23,534,365 1,837,125 -10.6%
2015-04-28 01:32 2015-04-23 GOLDSTEIN DOV A MD Director SELL $108.22 217,469 $23,534,365 1,837,125 -10.6%
2015-03-23 23:06 2015-03-19 ENRIGHT PATRICK G Director SELL $111.66 500,000 $55,831,600 18,361 -96.5%
2014-11-20 00:06 2014-11-17 Longitude Capital Partners, LLC 10% owner SELL $32.78 487,130 $15,966,173 28,186 -94.5%
2014-11-20 00:05 2014-11-17 ENRIGHT PATRICK G Director, 10% owner SELL $32.78 487,130 $15,966,173 28,186 -94.5%
2014-10-22 01:53 2014-10-21 JANNEY DANIEL Director, 10% owner BUY $20.00 500,000 $10,000,000 2,552,189 +24.4%
2014-10-22 02:33 2014-10-21 Alta Partners VIII, L.P. 10% owner BUY $20.00 500,000 $10,000,000 2,552,189 +24.4%
2014-10-22 00:31 2014-10-21 OMENN GILBERT S Director BUY $20.00 5,000 $100,000 5,000 +100.0%
2014-10-21 19:15 2014-10-21 DOMAIN PARTERS VII L P 10% owner BUY $20.00 500,000 $10,000,000 2,566,935 +24.2%
2014-10-14 13:54 2014-10-09 Longitude Capital Partners, LLC 10% owner SELL $30.00 943 $28,290 37,757 -2.4%
2014-10-14 13:51 2014-10-09 ENRIGHT PATRICK G Director, 10% owner SELL $30.00 943 $28,290 37,757 -2.4%
2014-10-09 23:02 2014-10-07 Longitude Capital Partners, LLC 10% owner SELL $30.04 11,927 $358,289 37,776 -24.0%
2014-10-09 23:03 2014-10-07 ENRIGHT PATRICK G Director, 10% owner SELL $30.04 11,927 $358,289 37,776 -24.0%
2013-07-02 23:55 2013-07-01 DOMAIN PARTERS VII L P 10% owner BUY $14.00 280,923 $3,932,922 2,066,935 +15.7%
2013-07-03 00:00 2013-07-01 DP VII ASSOCIATES LP 10% owner BUY $14.00 4,791 $67,074 35,253 +15.7%
2013-07-02 23:51 2013-07-01 Halak Brian K 10% owner BUY $14.00 285,714 $3,999,996 35,253 +100.0%
2013-07-02 23:40 2013-07-01 SCHOEMAKER KATHLEEN K 10% owner BUY $14.00 285,714 $3,999,996 35,253 +100.0%
2013-07-02 23:48 2013-07-01 DOVEY BRIAN H 10% owner BUY $14.00 285,714 $3,999,996 35,253 +100.0%
2013-07-02 23:31 2013-07-01 VITULLO NICOLE Director, 10% owner BUY $14.00 285,714 $3,999,996 35,253 +100.0%
2013-07-03 00:03 2013-07-01 BLAIR JAMES C 10% owner BUY $14.00 285,714 $3,999,996 35,253 +100.0%
2013-07-02 23:35 2013-07-01 TREU JESSE I 10% owner BUY $14.00 285,714 $3,999,996 35,253 +100.0%
2013-07-01 23:40 2013-07-01 Longitude Capital Partners, LLC 10% owner BUY $14.00 216,676 $3,033,464 38,011 +100.0%
2013-07-01 23:36 2013-07-01 ENRIGHT PATRICK G Director, 10% owner BUY $14.00 216,676 $3,033,464 38,011 +100.0%
2013-07-01 23:39 2013-07-01 MAYLEBEN TIMOTHY M Director, Officer - President and CEO BUY $14.00 5,000 $70,000 28,814 +21.0%
2013-07-01 23:38 2013-07-01 NEWTON ROGER S Director, Officer - Executive Chairman, CSO BUY $14.00 42,346 $592,844 629,683 +7.2%
2013-07-01 23:38 2013-07-01 LANGE LOUIS G Director BUY $14.00 14,214 $198,996 197,703 +7.7%
2013-07-01 23:34 2013-07-01 JANNEY DANIEL Director BUY $14.00 235,714 $3,299,996 2,052,189 +13.0%
2013-07-01 23:33 2013-07-01 Alta Partners VIII, L.P. 10% owner BUY $14.00 235,714 $3,299,996 2,052,189 +13.0%
2013-07-01 23:33 2013-07-01 Aisling Capital II LP 10% owner BUY $14.00 238,119 $3,333,666 2,054,594 +13.1%
2013-07-01 23:37 2013-07-01 GOLDSTEIN DOV A MD Director BUY $14.00 238,119 $3,333,666 2,054,594 +13.1%
2004-02-05 01:57 2004-01-30 BLAIR HENRY E Director OPT+S $34.60 10,000 $346,000 0 0.0%
SHOW ENTRIES

How to Interpret $ESPR Trades

Not every insider transaction in Esperion Therapeutics, Inc. is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $ESPR shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.

Data Source & Accuracy for ESPR

Insider activity data for Esperion Therapeutics, Inc. is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $ESPR, allowing you to follow the capital of those with the most intimate knowledge of the company.

UNDERSTANDING THE DATA

FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.

TRADE DATE: The actual day the insider executed the purchase or sale in the market.

INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.

OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.

CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.

TRADE TYPES DEFINITIONS

BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.

SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.

OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.